Shares of Cytek Biosciences (NASDAQ: CTKB) surged over 7% in pre-market trading on Monday, November 6th, after the life sciences technology company reported better-than-expected third-quarter results and raised its full-year revenue guidance.
For the three months ended September 30, 2024, Cytek posted total revenue of $51.5 million, representing a 7% year-over-year increase and topping analysts' estimates of $50.7 million. The company's product revenue grew 14% sequentially and 3% compared to Q3 2023, while service revenue saw a 25% jump year-over-year.
More importantly, Cytek swung to a GAAP net income of $0.9 million, compared to a net loss of $6.5 million in the prior-year quarter. The company also reported positive adjusted EBITDA of $7.6 million, driven by disciplined expense management and revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.